Published in BMJ on April 25, 1998
Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health (2003) 4.67
A randomised controlled trial of the effect of educational outreach by community pharmacists on prescribing in UK general practice. Br J Gen Pract (2002) 4.37
Developing valid cost effectiveness guidelines: a methodological report from the north of England evidence based guideline development project. Qual Health Care (2000) 1.26
Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages. Lipids Health Dis (2010) 0.81
Aspirin prophylaxis for vascular disease. Carotid endarterectomy should have been mentioned. BMJ (1998) 0.75
Aspirin prophylaxis for vascular disease. Knowledge needs to be used in clinical situations. BMJ (1998) 0.75
Extrapolation of trial results suggests that aspirin is useful in intermittent claudication. BMJ (1998) 0.75
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med (1983) 6.00
A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J (1974) 3.80
Controlled trial of aspirin in cerebral ischemia. Stroke (1977) 3.48
North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. BMJ (1998) 3.14
Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet (1991) 3.02
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med (1985) 2.99
The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (1989) 2.97
Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA (1992) 2.52
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry (1991) 2.49
The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol (1993) 2.39
Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation (1990) 2.38
The FDA's critique of the anturane reinfarction trial. N Engl J Med (1980) 2.20
Aspirin and secondary mortality after myocardial infarction. Lancet (1980) 2.12
"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke (1983) 2.09
A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med (1978) 1.68
Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke (1983) 1.56
Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol (1986) 1.52
The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. Lancet (1987) 1.50
Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J (1993) 1.45
Controlled trial of dipyridamole in cerebral vascular disease. Br Med J (1969) 1.41
Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction. Lancet (1988) 1.38
Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet (1985) 1.36
United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br Med J (Clin Res Ed) (1988) 1.29
Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology (1991) 1.28
High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. Stroke (1987) 1.26
A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA (1980) 1.23
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis (1980) 1.22
Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation (1993) 1.20
Controlled trial of aspirin in cerebral ischemia. Part II: surgical group. Stroke (1978) 1.19
[Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial]. Rev Neurol (Paris) (1982) 1.18
Who needs antiplatelet therapy? Br J Gen Pract (1996) 1.10
Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes (1989) 1.10
Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke (1988) 1.10
Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation (1980) 1.06
Sulfinpyrazone in the prevention of sudden death after myocardial infarction. The Anturane Reinfarction Trial Research Group. N Engl J Med (1980) 1.04
Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med (1990) 1.03
Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care (1986) 1.03
The Canadian trial of aspirin and sulfinpyrazone in threatened stroke. Am Heart J (1980) 1.02
[The treatment of transitory ischemic attacks with acetylsalicylic acid: results of a double-blind-study (author's transl)]. MMW Munch Med Wochenschr (1980) 1.01
Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA (1967) 1.00
Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology (1988) 0.98
The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results. Stroke (1988) 0.95
Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med (1989) 0.95
Controlled trial of aspirin in cerebral ischemia: an addendum. Neurology (1986) 0.94
Proceedings: The effect of a platelet inhibiting drug (sulfinpyrazone) in the therapy of patients with transient ischemic attacks (Tia's) and minor strokes. Thromb Diath Haemorrh (1975) 0.93
A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke (1985) 0.93
[Prevention of reinfarction with acetylsalicylic acid]. Folia Haematol Int Mag Klin Morphol Blutforsch (1979) 0.92
The Anturane Reinfarction Trial: reevaluation of outcome. N Engl J Med (1982) 0.91
Platelet adhesiveness in patients with cerebral vascular disease. Atherosclerosis (1972) 0.91
Aspirin and secondary mortality after myocardial infarction. Circulation (1980) 0.90
Sulphinpyrazone in post-myocardial infarction. Report from the Anturan Reinfarction Italian Study. Lancet (1982) 0.90
The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. Circulation (1980) 0.90
Intermittent claudication: Suloctidil v.s. placebo treatment. Vasa (1984) 0.89
The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation (1980) 0.87
Dipyridamole: a controlled trial of its effect in acute myocardial infarction. Br Med J (1968) 0.87
[Late results of conservative therapy of arterial occlusive diseases]. Internist (Berl) (1984) 0.87
Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol (1990) 0.86
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: I. Design, methods, and baseline characteristics. Control Clin Trials (1984) 0.86
[Effect of ticlopidine on peripheral obliterating arteriopathy]. Dtsch Med Wochenschr (1984) 0.86
Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Angiology (1982) 0.85
Effects of the platelet inhibitor ticlopidine on exercise tolerance in stable angina pectoris. Eur Heart J (1987) 0.85
A double-blind trial of suloctidil v. placebo in intermittent claudication. Br J Surg (1982) 0.84
Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis (1967) 0.84
[Controlled cooperative trial of secondary prevention of cerebral ischemic accidents caused by atherosclerosis, using aspirin and dipyridamole]. Presse Med (1983) 0.84
A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clin Nephrol (1984) 0.84
Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol (1982) 0.84
[Evaluation of oral drugs for intermittent claudication of the legs in phase III clinical trials. Options selected for the ACT study]. Therapie (1986) 0.84
Trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J (Clin Res Ed) (1981) 0.83
Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo. Curr Med Res Opin (1976) 0.83
Efficacy of indobufen in the treatment of intermittent claudication. Angiology (1988) 0.83
The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial. Thromb Haemost (1985) 0.83
Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study). Agents Actions Suppl (1984) 0.83
Aspirin in coronary heart disease. The Coronary Drug Project Research Group. Circulation (1980) 0.82
Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost (1985) 0.82
[Treatment of unstable angina with dipyridamole combined with low doses of aspirin. A multicenter pilot double-blind controlled study]. Minerva Cardioangiol (1992) 0.82
Transient cerebral ischaemic attacks--management and prognosis. Postgrad Med J (1981) 0.82
A randomized trial of aspirin and sulfinpyrazone in patients with threatened stroke. Results and methodologic issues. Circulation (1980) 0.82
Controlled trial of suloctidil in intermittent claudication. J Cardiovasc Pharmacol (1981) 0.82
Aspirin in coronary heart disease. The Coronary Drug Project Research Group. J Chronic Dis (1976) 0.81
Effect of low dose acetylsalicylic acid on the frequency and hematologic activity of left ventricular thrombus in anterior wall acute myocardial infarction. Am J Cardiol (1989) 0.80
Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. ISIS (International Studies of Infarct Survival) pilot study. Eur Heart J (1987) 0.78
Unstable angina: status of aspirin and other forms of therapy. Circulation (1985) 0.78
The anturane reinfarction trial. Circulation (1980) 0.77
Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group. Eur Heart J (1991) 0.77
Clinical study of ticlopidine in diabetic retinopathy. Belgian Ticlopidine Retinopathy Study Group (BTRS). Ophthalmologica (1992) 0.77
Low dose aspirin after early thrombolysis in anterior wall acute myocardial infarction. Am J Cardiol (1988) 0.77
The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group. Circulation (1980) 0.77
The use of statins: a case of misleading priorities? BMJ (1997) 13.35
Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2007) 7.25
Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2001) 7.24
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ (1993) 7.14
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ (2000) 6.67
Developing and implementing clinical practice guidelines. Qual Health Care (1995) 6.52
WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database Syst Rev (2007) 6.02
beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (1999) 5.66
North of England evidence based guidelines development project: guideline for the primary care management of dementia. BMJ (1998) 4.39
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequate. BMJ (1999) 3.60
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci (2001) 3.50
Promoting cost effective prescribing. BMJ (1995) 3.46
North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. BMJ (1998) 3.14
Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2000) 3.04
Social deprivation and prognostic benefits of cardiac surgery: observational study of 44 902 patients from five hospitals over 10 years. BMJ (2009) 2.95
Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ (2000) 2.92
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 2.61
Something rotten in the state of clinical and economic evaluations? Health Econ (1994) 2.50
Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2000) 2.33
EUR-ASSESS Project Subgroup Report on Dissemination and Impact. Int J Technol Assess Health Care (1997) 2.18
When is it cost-effective to change the behavior of health professionals? JAMA (2001) 2.08
Carcinogenic activity of bracken. Nature (1965) 2.03
How to develop cost-conscious guidelines. Health Technol Assess (2001) 2.03
The evidence for beta blockers in heart failure. BMJ (1999) 1.84
Audit and feedback versus alternative strategies: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2000) 1.79
Computer support for determining drug dose: systematic review and meta-analysis. BMJ (1999) 1.79
Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail (1999) 1.75
Cost-effectiveness league tables: more harm than good? Soc Sci Med (1993) 1.74
Economics of treatment of depression. Br J Psychiatry (1995) 1.74
Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace (2007) 1.73
Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol (2001) 1.69
Cardiovascular safety of fexofenadine HCl. Am J Cardiol (1999) 1.69
Reporting guidelines for economic studies. Health Econ (1995) 1.62
Development of a composite endpoint for randomized controlled trials in liver surgery. Br J Surg (2011) 1.58
"No thank you": why elderly patients declined to participate in a research study. Pharm World Sci (2001) 1.56
Clinical and economic consequences of dyspepsia in the community. Gut (2002) 1.55
Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2000) 1.53
Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer (2008) 1.53
Mass media interventions: effects on health services utilisation. Cochrane Database Syst Rev (2000) 1.50
Lessons from international experience in controlling pharmaceutical expenditure. II: Influencing doctors. BMJ (1996) 1.50
Psychiatric illness and mortality after hip fracture. Lancet (2001) 1.49
The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail (2001) 1.49
Elevations of serum T3 levels and their association with symptoms in World War II veterans with combat-related posttraumatic stress disorder: replication of findings in Vietnam combat veterans. Psychosom Med (1999) 1.49
SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev (2000) 1.48
Aspirin and acute myocardial infarction: clarifying the message. Br J Gen Pract (1995) 1.48
Can Wilson's disease patients be decoppered? Lancet (1989) 1.47
CONSORT: an important step toward evidence-based health care. Consolidated Standards of Reporting Trials. Ann Intern Med (1997) 1.43
A randomized trial of Evidence-based OutReach (EBOR): rationale and design. Control Clin Trials (1999) 1.42
General practice estimates of the prevalence of common chronic conditions. Ir Med J (1992) 1.39
Cost-effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs)-what makes a NSAID good value for money? Rheumatology (Oxford) (2000) 1.38
Computerised advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev (2001) 1.38
Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev (2000) 1.33
Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations. Leukemia (2005) 1.31
Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry. BMJ (1996) 1.30
Role of the medullary perfusion defect in the pathogenesis of ischemic renal failure. Kidney Int (1984) 1.29
Calcium supplementation for the management of primary hypertension in adults. Cochrane Database Syst Rev (2006) 1.29
Independent predictors of revision following metal-on-metal hip resurfacing: a retrospective cohort study using National Joint Registry data. J Bone Joint Surg Br (2012) 1.26
Developing valid cost effectiveness guidelines: a methodological report from the north of England evidence based guideline development project. Qual Health Care (2000) 1.26
Conventions for the reporting of nuclear magnetic shielding (or shift) tensors suggested by participants in the NATO ARW on NMR shielding constants at the University of Maryland, College Park, July 1992. Solid State Nucl Magn Reson (1993) 1.23
Valuing the effects of sildenafil in erectile dysfunction. Strong assumptions are required to generate a QALY value. BMJ (2000) 1.23
Independent predictors of failure up to 7.5 years after 35 386 single-brand cementless total hip replacements: a retrospective cohort study using National Joint Registry data. Bone Joint J (2013) 1.23
Choosing an appropriate unit of analysis in trials of interventions that attempt to influence practice. J Health Serv Res Policy (1999) 1.23
Changing doctor prescribing behaviour. Pharm World Sci (1999) 1.20
Hormone profiles in humans experiencing military survival training. Biol Psychiatry (2000) 1.19
Successful laparoscopic repair of paraesophageal hernia. Arch Surg (1995) 1.18
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant (2001) 1.16
Bicycle accidents and injuries among adult cyclists. Am J Sports Med (1986) 1.16
Late referral for dialysis: improving the management of chronic renal disease. QJM (2002) 1.15
Magnesium supplementation for the management of essential hypertension in adults. Cochrane Database Syst Rev (2006) 1.14
Cardiac abnormalities in myotonic dystrophy. Electrophysiologic and histopathologic studies. Am J Med (1979) 1.13
Distribution of toxin in molluscan shellfish following the occurrence of mussel toxicity in North-East England. Nature (1968) 1.13
Histochemical and ultrastructural modification of mucosal mast cell granules in parasitized mice lacking the beta-chymase, mouse mast cell protease-1. Am J Pathol (1998) 1.12
Audit of use of ACE inhibitors and monitoring in general practice. Guidelines on monitoring, on their own, are not sufficient. BMJ (1999) 1.11
Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm (2000) 1.10